Clinical trial
Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and…
NCT00156312 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00156312 |
|---|---|
| Title | Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine |
| Official title | Evaluation of Thymidine Phosphorylase and Other Predictive/Prognostic Factors in Primary Breast Cancer Treated With Docetaxel and Capecitabine (DC) |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine |
| Enrollment | 25 |
| Start date | Jul 1, 2003 |
| Primary completion | May 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: